GetTopicDetailResponse(id=f62f105100c2, topicName=內(nèi)皮素受體, introduction=內(nèi)皮素受體, content=null, image=null, comments=3, allHits=1123, url=null, type=0, isShow=1, status=1, isAdmin=null, adminId=4754896, adminEncryptionId=f63e4754896, adminName=俠膽醫(yī)心, createdBy=f63e4754896, createdName=俠膽醫(yī)心, createdAvatar=, createdTime=Sat Dec 31 12:55:05 CST 2022, time=2022-12-31, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=468970, tagList=[TagDto(tagId=468970, tagName=內(nèi)皮素受體)], ipAttribution=上海, topicAdmin=0, lengthMark=null)
[GetTopicListResponse(id=2118574, encodeId=824b21185e415, content=<a href='/topic/show?id=911910509896' target=_blank style='color:#2F92EE;'>#阿普昔騰坦#</a>（<a href='/topic/show?id=0c911050999b' target=_blank style='color:#2F92EE;'>#aprocitentan#</a>），該藥物是靶向<a href='/topic/show?id=f62f105100c2' target=_blank style='color:#2F92EE;'>#內(nèi)皮素受體#</a>的口服小分子<a href='/topic/show?id=1c1710265113' target=_blank style='color:#2F92EE;'>#高血壓#</a><a href='/topic/show?id=0bad820e112' target=_blank style='color:#2F92EE;'>#肺動脈高壓#</a>, objectTitle=Lancet：科學(xué)家開發(fā)出基于新機(jī)制的降血壓藥, objectType=article, longId=751569, objectId=614be51569b9, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20221212/1670824230004_5579292.png, objectUrl=/article/show_article.do?id=614be51569b9, replyNumber=0, likeNumber=126, createdTime=2023-03-10, rootId=0, userName=showtest, userId=8f0715, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=614be51569b9, moduleTitle=Lancet：科學(xué)家開發(fā)出基于新機(jī)制的降血壓藥, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=614be51569b9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2108278, encodeId=d21e21082e8de, content=<a href='/topic/show?id=911910509896' target=_blank style='color:#2F92EE;'>#阿普昔騰坦#</a>（<a href='/topic/show?id=0c911050999b' target=_blank style='color:#2F92EE;'>#aprocitentan#</a>），該藥物是靶向<a href='/topic/show?id=f62f105100c2' target=_blank style='color:#2F92EE;'>#內(nèi)皮素受體#</a>的口服小分子。之前的研究顯示<a href='/topic/show?id=1ebc1001392e' target=_blank style='color:#2F92EE;'>#頑固性高血壓#</a>患者體內(nèi)控制血管收縮的內(nèi)皮素信號通路被異常激活。臨床研究表明aprocitentan可明顯降低受試患者的舒張壓和收縮壓，特別是頑固性高血壓患者療效的持續(xù)時間超過48周?；颊咦畛Ｒ姷闹委煱榘l(fā)不良反應(yīng)為輕中度的體內(nèi)液體滯留，并且多數(shù)可控。<a href='/topic/show?id=1c1710265113' target=_blank style='color:#2F92EE;'>#高血壓#</a>, objectTitle=持續(xù)降壓一年！這款新型降壓藥有何特殊之處？, objectType=article, longId=748872, objectId=5ab0e4887268, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20221207/1670413739763_8252897.webp, objectUrl=/article/show_article.do?id=5ab0e4887268, replyNumber=0, likeNumber=131, createdTime=2022-12-31, rootId=0, userName=俠膽醫(yī)心, userId=f63e4754896, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=5ab0e4887268, moduleTitle=持續(xù)降壓一年！這款新型降壓藥有何特殊之處？, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=5ab0e4887268)], followStatus=false, userIsMember=false, type=1, lengthMark=1)]
俠膽醫(yī)心
2022-12-31發(fā)表于上海
